Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of allogeneic bone marrow-derived mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease
MOH_2025-12-25_015561Phase 2Recruiting
- Sponsor
- Hadassah Medical Center
- Start
- Jun 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Hadassah Medical Center. Primary endpoints: Safety and Efficacy. Started Jun 2022; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2025-12-25_015561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-25_015561.